Detalhe da pesquisa
1.
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Blood
; 140(21): 2248-2260, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839452
2.
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Br J Haematol
; 203(2): 182-193, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37386897
3.
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.
Am J Hematol
; 98(6): E134-E138, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882876
4.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
N Engl J Med
; 379(10): 934-947, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30184451
5.
18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.
Expert Rev Hematol
; 17(1-3): 95-100, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299464
6.
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Front Immunol
; 15: 1293931, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38469299
7.
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
J Clin Oncol
; 41(33): 5107-5117, 2023 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506346
8.
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
Transplant Cell Ther
; 29(12): 747.e1-747.e10, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659694
9.
Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study.
Cancer Med
; 12(6): 6536-6546, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36373169
10.
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
J Clin Oncol
; 40(11): 1196-1205, 2022 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030036
11.
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
Leuk Lymphoma
; 63(1): 93-100, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34459702
12.
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Int J Hematol
; 116(3): 381-392, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35551632
13.
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
Leuk Lymphoma
; 63(9): 2063-2073, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35503708
14.
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
Front Immunol
; 13: 855730, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35911769
15.
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Clin Cancer Res
; 28(17): 3658-3668, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35727601
16.
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.
Cancers (Basel)
; 13(18)2021 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34572849
17.
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Cancer Med
; 10(10): 3214-3223, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33932100
18.
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
J Immunother Cancer
; 9(6)2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158317
19.
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Blood Cancer J
; 14(1): 83, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38760376
20.
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Hemasphere
; 8(4): e70, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38650598